Shares of DelMar Pharmaceuticals (NASDAQ:DMPI) have received a consensus broker rating score of 1.50 (Buy) from the four brokers that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and three have issued a strong buy rating on the company.
Brokers have set a twelve-month consensus price target of $11.16 for the company and are expecting that the company will post ($0.10) earnings per share for the current quarter, according to Zacks. Zacks has also assigned DelMar Pharmaceuticals an industry rank of 173 out of 265 based on the ratings given to its competitors.
Separately, HC Wainwright set a $12.00 target price on DelMar Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, January 4th.
An institutional investor recently bought a new position in DelMar Pharmaceuticals stock. Susquehanna International Group LLP bought a new position in shares of DelMar Pharmaceuticals (NASDAQ:DMPI) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 364,496 shares of the company’s stock, valued at approximately $306,000. Susquehanna International Group LLP owned approximately 1.69% of DelMar Pharmaceuticals at the end of the most recent quarter. Institutional investors own 5.50% of the company’s stock.
Shares of DMPI opened at $1.06 on Monday. The stock has a market capitalization of $23.32, a price-to-earnings ratio of -1.43 and a beta of 1.47. DelMar Pharmaceuticals has a 52 week low of $0.78 and a 52 week high of $3.19.
DelMar Pharmaceuticals (NASDAQ:DMPI) last released its earnings results on Thursday, February 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01. sell-side analysts expect that DelMar Pharmaceuticals will post -0.46 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Analysts Anticipate DelMar Pharmaceuticals (DMPI) to Announce ($0.10) Earnings Per Share” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/16/analysts-anticipate-delmar-pharmaceuticals-dmpi-to-announce-0-10-earnings-per-share.html.
DelMar Pharmaceuticals Company Profile
DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in Phase III study for the treatment of recurrent glioblastoma multiforme.
Get a free copy of the Zacks research report on DelMar Pharmaceuticals (DMPI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.